Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (801-810 of 853) with videos related to

Pageof 86
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
British Journal of Cancer|July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumoursS D Fosså, S P Stenning, A Gerl, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2018
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trialsRaghav Sundar, Terri McVeigh, David Dolling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Pageof 86

Showing results (801-810 of 853) with videos related to

Sort By:
Pageof 86
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2006
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignanciesChooi P Lee, Maja J A de Jonge, Anne E O'Donnell, et al.
British Journal of Cancer|July 29, 1999
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumoursS D Fosså, S P Stenning, A Gerl, et al.
Oncotarget|April 29, 2017
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancerSaeed Rafii, Charlie Gourley, Rajiv Kumar, et al.
British Journal of Cancer|August 23, 2012
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albuminA Ploquin, D Olmos, D Lacombe, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2018
Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trialsRaghav Sundar, Terri McVeigh, David Dolling, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I databaseP A Cassier, V Polivka, I Judson, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancerGerhardt Attard, Alison H M Reid, Roger A'Hern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotypeCharlie Gourley, Caroline O Michie, Patricia Roxburgh, et al.
Pageof 86